Gemfibrozil
- TRADE NAMES: Bolutol; Decrelip; Fibrocit; Gemlipid; Gen-Fibro; Gevilon Uno; Jezil; Lipur; Lopid (Pfizer); Nu-Gemfibrozil
- INDICATIONS: Hyperlipidemia
- CLASS: Fibrate, Lipid regulator
- HALF-LIFE: 2 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atorvastatin, Bexarotene, Colchicine, Cyclosporine, Dicumarol, Eluxadoline, Enzalutamide, Ezetimibe, Fluvastatin, Interferon Alfa, Lovastatin, Nicotinic acid, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Ozanimod, Paclitaxel, Pioglitazone, Pitavastatin, Pravastatin, Repaglinide, Rosiglitazone, Rosuvastatin, Roxithromycin, Selexipag, Simvastatin, Treprostinil, Tucatinib, Warfarin
PREGNANCY CATEGORY: C
Contra-indicated in patients with preexisting gallbladder disease.
Please login to see the rest of this drug profile
SKIN.
NAILS.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RENAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric